Abstracts tagged "Adverse events"

Abstract Number: 2332 • 2016 ACR/ARHP Annual Meeting
Midterm Outcome of Modular Metal-on-Metal Total Hip Arthroplasty
Hiroki Wakabayashi¹, Masahiro Hasegawa², Toshio Yamaguchi³, Yohei Naito⁴ and Akihiro Sudo⁵, ¹Department of Orthopaedic Surgery, Graduate School of Medicine, Mie University, Tsu City, Japan, ²Department of Orthopaedic Surgery, Mie University Graduate School of Medicine, Tsu City, Mie, Japan, ³Department of Orthopaedic Surgery, Mie University Graduate School of Medicine, Tsu, Japan, ⁴Department of Orthopaedic Surgery, Graduate School of Medicine, Mie University, Tsu City, Mie, Japan, ⁵Department of Orthopaedic Surgery, Mie University Graduate School of Medicine, Tsu City, Japan
Background/Purpose: Wear, osteolysis, and late aseptic loosening associated with ultrahigh-molecular-weight polyethylene components used in total hip arthroplasties (THA) have led to increased interest in metal-on-metal…
Abstract Number: 2444 • 2016 ACR/ARHP Annual Meeting
Effects of Disease Activity and Drug Exposure on Pregnancy Outcomes with Inflammatory Arthritis
Emily Fishman¹, Kathryn H. Dao² and John J. Cush³, ¹Texas A&M HSC College of Medicine, Dallas, TX, ²Texas Health, Dallas, TX, ³Baylor Research Institute, Dallas, TX
Background/Purpose: Pregnancy is often encountered in women who have inflammatory arthritis (IA), such as rheumatoid arthritis (RA), psoriatic arthritis (PsA), juvenile arthritis (JIA) or ankylosing…
Abstract Number: 2547 • 2016 ACR/ARHP Annual Meeting
Quantification of Adverse Glucocorticoid Effects on Skin in Rheumatoid Arthritis
Frank Buttgereit¹, Jonna Amann², Friederike Breitenfeldt³, Dörte Huscher⁴, Johannes WJ Bijlsma⁵ and Johannes WG Jacobs⁶, ¹Department of Rheumatology and Clinical Immunology, Charité – Universitätsmedizin Berlin, Berlin, Germany, ²Department of Rheumatology and Clinical Immunology, Charité University Medicine, Berlin, Germany, ³Department of Rheumatology and Clinical Immunology, Charité University Hospital, Berlin, Germany, ⁴Charité-University Hospital and German Rheumatism Research Centre, Berlin, Germany, ⁵ARC, Amsterdam, Netherlands, ⁶Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands
Background/Purpose: Glucocorticoids (GCs) are frequently and often chronically used for the treatment of rheumatoid arthritis (RA) and other immune diseases and vasculitis. An estimated 0.8–1.2%…
Abstract Number: 2595 • 2016 ACR/ARHP Annual Meeting
Real World Results from a Post-Approval Safety Surveillance of Tofacitinib (Xeljanz): Over 3 Year Results from an Ongoing US-Based Rheumatoid Arthritis Registry
Arthur F. Kavanaugh¹, Jamie Geier², Clifton Bingham III³, Connie Chen², George W. Reed^4,5, Katherine C. Saunders⁴, Yan Chen⁶, Andrew Koenig⁶, Laura Cappelli⁷, Jeffrey D. Greenberg^4,8 and Joel M. Kremer⁹, ¹University of California, San Diego School of Medicine, LaJolla, CA, ²Pfizer, Inc., New York, NY, ³Johns Hopkins University, Baltimore, MD, ⁴Corrona, LLC, Southborough, MA, ⁵University of Massachusetts Medical School, Worcester, MA, ⁶Pfizer, Inc., Collegeville, PA, ⁷Medicine/Rheumatology, Johns Hopkins University, Baltimore, MD, ⁸NYU School of Medicine, New York, NY, ⁹Albany Medical College and the Center for Rheumatology, Albany, NY
Background/Purpose: An interim analysis of a prospective observational 3+ year study, embedded within the US Corrona Rheumatoid Arthritis (RA) registry (14 years and ongoing), was…
Abstract Number: 2629 • 2016 ACR/ARHP Annual Meeting
Serious Adverse Events in Patients with RA Taking Abatacept Compared with Other Dmards. Results from a US-Wide Safety Registry
Kaleb Michaud^1,2, Sofia Pedro², TA Simon³, Frederick Wolfe² and Rebecca Schumacher², ¹University of Nebraska Medical Center, Omaha, NE, ²National Data Bank for Rheumatic Diseases, Wichita, KS, ³Bristol-Myers Squibb, Princeton, NJ
Background/Purpose: Observational studies are critical in assessing medication safety and effectiveness in the real world. Nonrandom assignment can provide insight to how and when medications…
Abstract Number: 2970 • 2016 ACR/ARHP Annual Meeting
Incidence and Characteristics of Vasculitis Associated with Monoclonal Antibodies and Peptide Fusion Proteins: A Survey from the French National Pharmacovigilance Database
Bertrand Lioger^1,2, Fanny Hennekinne¹, Marie-Sara Agier³, Annie-Pierre Jonville-Bera^3,4 and François Maillot^1,5, ¹Internal Medicine, Tours University Hospital, Tours, France, ²GICC UMR 7292, University François Rabelais, Tours, France, ³Clinical Pharmacology, Tours University Hospital, Tours, France, ⁴Regional Pharmacovigilance Center, Tours University Hospital, Tours, France, ⁵INSERM U1069, University François Rabelais, Tours, France
Background/Purpose: Immunological classes of adverse events (AEs), including the immune related AEs and the paradoxical effects, have emerged with the used of biologics. Among them,…
Abstract Number: 3141 • 2016 ACR/ARHP Annual Meeting
Development of a Glucocorticoid Toxicity Index Using Multi-Criteria Decision Analysis
Eli Miloslavsky¹, Raymond P. Naden², Johannes WJ Bijlsma³, Paul Brogan⁴, Sherwood Brown⁵, Paul Brunetta⁶, Frank Buttgereit⁷, Hyon K. Choi⁸, Jean-Francois Dicaire⁹, Jeffrey Gelfand¹⁰, Liam Heaney¹¹, Liz Lightstone¹², Leo Lu¹³, Dedee Murrell¹⁴, Michelle Petri¹⁵, James T. Rosenbaum¹⁶, Kenneth Saag¹⁷, Murray Urowitz¹⁸, Kevin L Winthrop¹⁹ and John H. Stone²⁰, ¹Division of Rheumatology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ²New Zealand Ministry of Health, New Zealand Ministry of Health, Auckland, New Zealand, ³ARC, Amsterdam, Netherlands, ⁴Department of Paediatric Rheumatology, UCL Institute of Child Health and Great Ormond Street Hospital NHS Foundation Trust, London, United Kingdom, ⁵Psychiatry, UT Southwestern Medical Center, Dallas, TX, ⁶Genentech, Inc., South San Francisco, CA, ⁷Rheumatology and Clinical Immunology, Charité - University Medicine Berlin, Berlin, Germany, ⁸Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁹Pinnacle Inc., Quebec, QC, Canada, ¹⁰Neurology, University of California San Francisco, San Francisco, CA, ¹¹Department of Respiratory Medicine, Queen's University Belfast, Belfast, Ireland, ¹²Department of Medicine, Imperial College London, London, England, ¹³Allergy, Immunology, and Rheumatology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ¹⁴Department of Dermatology, University of New South Wales, Sydney, Australia, ¹⁵Rheumatology Division, Johns Hopkins University School of Medicine, Baltimore, MD, ¹⁶Oregon Health & Science University, Portland, OR, ¹⁷Division of Clinical Immunology and Rheumatology, University of Alabama Birmingham School of Medicine, Birmingham, AL, ¹⁸Medicine, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ¹⁹Oregon Health and Sciences University, Portland, OR, ²⁰Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA
Background/Purpose: Glucocorticoids (GC) are associated with substantial treatment morbidity. New immunomodulatory agents offer the possibility of limiting GC exposure. To assess the comparative benefits of…
Abstract Number: 14 • 2016 ACR/ARHP Annual Meeting
Failure Predictors to Anti-Tumor Necrosis Antagonists in Patients with Chronic Arthritis: Results of a National Registry Biobadasar
Maria Jezabel Haye Salinas¹, Soledad Retamozo², Alejandro Alvarellos³, Francisco Caeiro⁴, Juan Pablo Pirola⁴, Diego Baenas¹, María Celina de La Vega⁵, Gustavo Casado⁶, Gimena Gomez⁷, Javier Roberti⁸, Osvaldo Luis Cerda⁹, Ignacio Javier Gandino¹⁰, Ana Quinteros¹¹, Ida Exeni^6,12, Juan Manuel Bande¹³, Juan Carlos Barreira¹⁴, Carla Gobbi¹⁵, Analia Alvarez¹⁶, Amelia Granel¹⁷, Alejandra Peluzzon¹⁸, Ana Capuccio¹⁹, Romina Nieto²⁰, Rossana Quintana²¹, Eduardo Mussano²², Santiago Scarafia²³, Carolina Costi²⁴, Mercedes De La Sota²⁵, Monica Patricia Diaz²⁶, Edson Javier Velozo²⁷, Santiago Aguero²⁸, Cristina Battagliotti²⁹, Sidney Soares de Souza³⁰, Emilia Cavillon³¹, Analia Bohr³², Andrea Smichowski³³, Daniela Vidal³⁴, Dora Pereira³⁵, Liliana Martinez³⁶, Luis Somma³⁷, Marta Zalazar³⁸, Pablo Finucci Curi³⁹, Leandro Carlevaris⁴⁰, Guillermo Berbotto⁴¹ and Veronica Saurit⁴, ¹Hospital Privado Centro Médico de Córdoba, Córdoba, Argentina, ²Rheumatology Unit, Hospital Privado Centro Médico de Córdoba, Argentina, Córdoba, Argentina, ³Rheumatology, Hospital Privado Centro Médico de Córdoba, Cordoba, Argentina, ⁴Rheumatology, Hospital Privado Centro Médico de Córdoba, Córdoba, Argentina, ⁵Sociedad Argentina de Reumatología, CABA, Argentina, ⁶Sociedad Argentina de Reumatologia, CABA, Argentina, ⁷Sociedad Argentina de Reumatología, Buenos Aires, Argentina, ⁸SAR, CABA, Argentina, ⁹IREP, CABA, Argentina, ¹⁰Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ¹¹Centro Integral Reumatológico, Tucuman, Argentina, ¹²Sanatorio Parque, Cordoba, Argentina, ¹³Hospital Tornú, CABA, Argentina, ¹⁴Rheumatology Unit, Hospital Britanico de Buenos Aires, CABA, Argentina, ¹⁵Rheumatology, Sanatorio Allende de Córdoba, Cordoba, Argentina, ¹⁶Hospital Penna, Bahía Blanca, Argentina, ¹⁷Centro Platense de Reumatología, La Plata, Argentina, ¹⁸Hospital Clínica José de San Martín, CABA, Argentina, ¹⁹Hospital Cesar Milstein, CABA, Argentina, ²⁰Hospital Provincial, Rosario, Argentina, ²¹Sanatorio Parque, Rosario, Argentina, ²²Córdoba, Hospital Nacional de Clínicas, Córdoba, Argentina, ²³Hospital Bernardino Rivadavia, CABA, Argentina, ²⁴Hospital San Martín, LaPlata, Argentina, ²⁵Consultorios, Bahia Blanca, Argentina, ²⁶Hospital Zonal Bariloche, Bariloche, Argentina, ²⁷Rheumatology, Sanatorio Adventista del Plata, Entre Rios, Argentina, ²⁸Sanatorio Pasteur, Catamarca, Argentina, ²⁹Hospital de Niños Dr Orlando Alasia, Santa Fé, Argentina, ³⁰Ramallo 1851, REUMAR, CABA, Argentina, ³¹Consultorio, Cordoba, Argentina, ³²Hospital de Rehabilitación Rocca, CABA, Argentina, ³³Atención Integral de Reumatología, CABA, Argentina, ³⁴Hospital de Niños de Córdoba, Córdoba, Argentina, ³⁵Centro Raquis, Buenos Aires, Argentina, ³⁶Hospital Fernandez, CABA, Argentina, ³⁷SOMMA, Buenos Aires, Argentina, ³⁸Hospital Pirovano, CABA, Argentina, ³⁹Centro Médico Mitre, Entre Rios, Argentina, ⁴⁰IARI, CABA, Argentina, ⁴¹Sanatorio Británico, Rosario, Argentina
Background/Purpose: to analyze failure predictors to anti-tumor necrosis (TNF) therapy in patients who have switched these drugs during chronic arthritis treatment. Methods: BIOBADASAR is a…
Abstract Number: 552 • 2015 ACR/ARHP Annual Meeting
The Relationship Between Efficacy and Toxicity in Patients with Rheumatoid Arthritis Receiving Methotrexate in Combination with Adalimumab
Gerd Burmester¹, Gurjit S. Kaeley², Arthur Kavanaugh³, Cem Gabay⁴, Daryl MacCarter⁵, Peter Nash⁶, Tsutomu Takeuchi⁷, Anabela Cardoso⁸, Shufang Liu⁹, Hartmut Kupper¹⁰ and Jasmina Kalabic¹¹, ¹Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany, ²University of Florida, Jacksonville, FL, ³University of California, San Diego School of Medicine, LaJolla, CA, ⁴Rheumatology, Geneva University Hospital, Geneva, Switzerland, ⁵Coeur d'Alene Arthritis Clinic, Coeur d'Alene, ID, ⁶Department of Medicine, University of Queensland, Brisbane, Australia, ⁷Keio University School of Medicine, Tokyo, Japan, ⁸Torre Oriente, AbbVie, Lisboa, Portugal, ⁹Immunology Development, AbbVie, North Chicago, IL, ¹⁰AbbVie Deutschland GmBH & Co. KG, Ludwigshafen, Germany, ¹¹AbbVie, North Chicago, IL
Background/Purpose: Combination treatment of rheumatoid arthritis (RA) with methotrexate (MTX)+adalimumab (ADA) has been shown to be more effective than ADA monotherapy. However, MTX is associated…
Abstract Number: 561 • 2015 ACR/ARHP Annual Meeting
Improvement in Disease Activity and the Long-Term Risk of Serious Infectious Events in Rheumatoid Arthritis Patients Treated with Certolizumab Pegol
Jeffrey R. Curtis¹, Marc de Longueville², Cathy O'Brien² and Boulos Haraoui³, ¹University of Alabama at Birmingham, Birmingham, AL, ²UCB Pharma, Brussels, Belgium, ³Department of Medicine, Centre Hospitalier de l'Université de Montréal, Montréal, QC, Canada
Background/Purpose: Anti-TNF drugs are an effective treatment option for rheumatoid arthritis (RA) patients (pts) but have been associated with an increased incidence of serious infectious…
Abstract Number: 573 • 2015 ACR/ARHP Annual Meeting
Association Between Three Measures of Oral Glucocorticoid Exposure and Potential Adverse Events Among Patients with Rheumatoid Arthritis
Jennie Best¹, Amanda Farr², Gregory Lenhart², Khaled Sarsour¹, Marni Stott-Miller² and Yong Gil Hwang³, ¹Genentech, South San Francisco, CA, ²Truven Health Analytics, Cambridge, MA, ³Department of Medicine, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Oral glucocorticoids are commonly used to treat rheumatoid arthritis (RA). However, their use may be associated with potential adverse events. Therefore, the objective was…
Abstract Number: 587 • 2015 ACR/ARHP Annual Meeting
Defining the Conditions Under Which Long-Term Glucocorticoid Treatment Has a Good Benefit-Risk Ratio
Cindy Strehl¹, Johannes W J Bijlsma², Maarten de Wit³, Maurizio Cutolo⁴, Raphaele Seror⁵, Kevin L. Winthrop⁶, Frank Buttgereit¹ and EULAR Task Force on Glucocorticoids, ¹Department of Rheumatology and Clinical Immunology, Charité University Medicine, Berlin, Germany, ²Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ³Medical Humanities, VU Medical Centre, Amsterdam, Netherlands, ⁴Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Genova, Italy, ⁵Department of Rheumatology, Assistance Publique–Hopitaux de Paris, Hôpitaux Universitaires Paris-Sud, Le Kremlin Bicêtre, France, ⁶Division of Infectious Diseases, Oregon Health and Science University, Portland, OR
Background/Purpose: Glucocorticoids (GC) are used to treat a wide range of inflammatory diseases including rheumatic and musculoskeletal diseases. EULAR recommendations on GC therapy are up…
Abstract Number: 619 • 2015 ACR/ARHP Annual Meeting
Long-Term Adverse Events after Daily Concomitant Treatment with 10mg Prednisone in the 2-Year Computer Assisted Management in Early Rheumatoid Arthritis Trial-II
Maria de Hair, Nicole IJff, Johannes Jacobs and Jacob van Laar, Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands
On behalf of the Society for Rheumatology Research Utrecht (SRU) Background/Purpose: To investigate the frequency of long-term adverse events (AEs) in early rheumatoid arthritis (RA)…
Abstract Number: 884 • 2015 ACR/ARHP Annual Meeting
Patient Perceptions of Treatment with Glucocorticoids in ANCA-Associated Vasculitis
Joanna Robson¹, Susan Ashdown², Jill Dawson³, Ebony Easley⁴, Don Gebhart⁵, Katherine Kellom⁶, Georgia Lanier⁷, Nataliya Milman⁸, Jacqueline Peck⁹, Judy A. Shea¹⁰, Peter F. Cronholm⁴ and Peter A. Merkel¹¹, ¹Nuffield Department of Orthopaedics Rheumatology and Musculoskeletal Sciences, Botnar Research Centre, University of Oxford, Oxford, United Kingdom, ²NONE, Branbury, United Kingdom, ³Nuffield Department of Population Health HSRU, University of Oxford, Oxford, United Kingdom, ⁴Department of Family Medicine and Community Health, The University of Pennsylvania, Philadelphia, PA, ⁵NONE, Columbus, OH, ⁶PolicyLab, Children's Hospital of Philadelphia, Philadelphia, PA, United Kingdom, ⁷NONE, Framingham, MA, ⁸Division of Rheumatology, University of Ottawa, Ottawa, ON, Canada, ⁹NONE, Oxford, United Kingdom, ¹⁰Division of General Internal Medicine, University of Pennsylvania, Philadelphia, PA, United Kingdom, ¹¹Penn Vasculitis Center, Division of Rheumatology, University of Pennsylvania, Philadelphia, PA
Background/Purpose: Granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA) and eosinophilic granulomatosis with polyangiitis (EGPA) comprise a group of multisystem diseases of the small blood vessels…
Abstract Number: 956 • 2015 ACR/ARHP Annual Meeting
The Addition of One or More Biologics to Methotrexate in Children with Juvenile Idiopathic Arthritis Increases the Incidence of Infections and Other Adverse Events
Joost Swart¹, Angela Pistorio², Francesca Bovis³, Ekaterina Alexeeva⁴, Michael Hofer⁵, Susan Nielsen⁶, Jordi Anton⁷, Alessandro Consolaro⁸, Violeta Vladislava Panaviene⁹, Valda Stanevicha¹⁰, Maria Trachana¹¹, Constantin Ailioaie¹², Florence Uettwiller¹³, Fabrizio De Benedetti¹⁴, Elena Tsitsami¹⁵, Berit Flato¹⁶, Pavla Dolezalová¹⁷, Tamás Constantin¹⁸, Troels Herlin¹⁹, Sylvia Kamphuis²⁰, Sujata Sawhney²¹, Despoina Maritsi²², Veronika Vargova²³, Luca Villa⁸, Chiara Pallotti⁸, Angelo Ravelli³, Alberto Martini²⁴, Nico Wulffraat²⁵, Nicolino Ruperto²⁶ and on behalf of for PRINTO, ¹Pediatric Rheumatology, Wilhelmina Children's Hospital/ UMC Utrecht, Utrecht, Netherlands, ²Servizio di Epidemiologia e Biostatistica, Istituto Giannina Gaslini, Genoa, Italy, ³Istituto Giannina Gaslini, Genoa, Italy, ⁴Rheumatology, Scientific Center of Children's Health of RAMS, Moscow, Russia, ⁵Pediatrie, Unité Romande de Rhumatologie Pédiatrique, Hospitalier Universitaire Vaudois, Lausanne, Switzerland, ⁶Pediatric Rheumatology Unit, Juliane Marie Centret, Rigshospitalet, Copenhagen, Denmark, ⁷Unitat de Reumatologia Pediàtrica, Hospital Sant Joan de Déu, Barcelona, Spain, ⁸Pediatria II - Reumatologia, PRINTO, Istituto Giannina Gaslini, Genoa, Italy, ⁹Centre of Pediatrics, Vilnius University, Vilnius, Lithuania, ¹⁰Department of Paediatrics, Riga Stradins University, Riga, Latvia, ¹¹1st Department of Pediatrics, Aristotle University, Thessaloniki, Greece, ¹²II Pediatric Clinic, Private Medical Clinic, IASI, Romania, ¹³Unité d'Immunologie, Hématologie et Rhumatologie Pediatrique, Université Paris-Descartes, IMAGINE Institute, Hôpital Necker-Enfants Malades, Paris, France, ¹⁴Reumatologia, Ospedale Pediatrico Bambino Gesù, Roma, Italy, ¹⁵First Department of Pediatrics, Children Hospital Aghia Sophia, Athens, Greece, ¹⁶Rheumatology, Oslo University Hospital, Oslo, Norway, ¹⁷Pediatric Rheumatology Unit, Department of Pediatrics and Adolescent Medicine, General University Hospital in Prague, Prague, Czech Republic, ¹⁸Unit of Paediatric Rheumatology, 2nd Dpt of Pediatrics, Semmelweis University, Budapest, Hungary, ¹⁹Department of Pediatrics, Aarhus University Hospital, Aarhus N, Denmark, ²⁰Pediatric Rheumatology, Erasmus MC Sophia Children's Hospital, Rotterdam, Netherlands, ²¹Paediatric rheumatology, Sir Ganga Ram Hospital, New Delhi, India, ²²2nd Department of Academic Pediatrics, Athens Medical School, university of Athens, Athens, Greece, ²³1st Department of Paediatrics and Adolescent Medicine, Šafarik University and Children Faculty Hospital in Košice, Kosice, Slovakia, ²⁴Istituto G. Gaslini, Pediatria II, PRINTO, and University of Genoa, Genoa, Italy, ²⁵Pediatric rheumatology, Wilhelmina Children's Hospital/ UMC Utrecht, Utrecht, Netherlands, ²⁶Istituto G. Gaslini, Pediatria II, PRINTO, Genoa, Italy
Background/Purpose: Treatment of juvenile idiopathic arthritis (JIA) has greatly changed in the past 15 years thanks to the introduction of biologic agents but little is…

« Previous Page
1
…
4
5
6
7
8
…
10
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].